Amarin Stock Jumps as Debate Moves to Heart Drug’s Potential Label
(Bloomberg) -- The unanimous panel backing to expand the label for Amarin Corp.’s heart drug Vascepa sparked debate across Wall Street as analysts and investors weighed whether the drug could be so...